2024
-
Richmond BW, Marshall CB, Blackburn JB, Tufenkjian TS, Lehmann BD, Han W, Newcomb D, Gutor SS, Hunt RP, Michell DL, Vickers KC, Polosukhin VV, Blackwell TS, Pietenpol JA. Loss of p73 Expression Contributes to Chronic Obstructive Pulmonary Disease. American journal of respiratory and critical care medicine. 2024 Jan 15;209(209). 153-163.
2023
-
Lehmann BD, Abramson VG, Dees EC, Shah PD, Ballinger TJ, Isaacs C, Santa-Maria CA, An H, Gonzalez-Ericsson PI, Sanders ME, Newsom KC, Abramson RG, Sheng Q, Hsu CY, Shyr Y, Wolff AC, Pietenpol JA. Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical Trial. JAMA oncology. 2023 Dec 14.
-
Xu GJ, Loberg MA, Gallant JN, Sheng Q, Chen SC, Lehmann BD, Shaddy SM, Tigue ML, Phifer CJ, Wang L, Saab-Chalhoub MW, Dehan LM, Wei Q, Chen R, Li B, Kim CY, Ferguson DC, Netterville JL, Rohde SL, Solórzano CC, Bischoff LA, Baregamian N, Shaver AC, Mehrad M, Ely KA, Byrne DW, Stricker TP, Murphy BA, Choe JH, Kagohara LT, Jaffee EM, Huang EC, Ye F, Lee E, Weiss VL. Molecular signature incorporating the immune microenvironment enhances thyroid cancer outcome prediction. Cell genomics. 2023 Oct 11;3(3). 100409 p.
-
Taylor BC, Sun X, Gonzalez-Ericsson PI, Sanchez V, Sanders ME, Wescott EC, Opalenik SR, Hanna A, Chou ST, Van Kaer L, Gomez H, Isaacs C, Ballinger TJ, Santa-Maria CA, Shah PD, Dees EC, Lehmann BD, Abramson VG, Pietenpol JA, Balko JM. NKG2A is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple Negative Breast Cancer. Cancer discovery. 2023 Oct 4.
-
Doha ZO, Wang X, Calistri NL, Eng J, Daniel CJ, Ternes L, Kim EN, Pelz C, Munks M, Betts C, Kwon S, Bucher E, Li X, Waugh T, Tatarova Z, Blumberg D, Ko A, Kirchberger N, Pietenpol JA, Sanders ME, Langer EM, Dai MS, Mills G, Chin K, Chang YH, Coussens LM, Gray JW, Heiser LM, Sears RC. MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer. Nature communications. 2023 Sep 13;14(14). 5665 p.
-
Zhang W, Li E, Wang L, Lehmann BD, Chen XS. Transcriptome Meta-Analysis of Triple-Negative Breast Cancer Response to Neoadjuvant Chemotherapy. Cancers. 2023 Apr 7;15(15).
2021
-
Redman-Rivera LN, Shaver TM, Jin H, Marshall CB, Schafer JM, Sheng Q, Hongo RA, Beckermann KE, Wheeler FC, Lehmann BD, Pietenpol JA. Acquisition of aneuploidy drives mutant p53-associated gain-of-function phenotypes. Nature communications. 2021 Dec 31;12(12). 5184 p.
-
Lehmann BD, Colaprico A, Silva TC, Chen J, An H, Ban Y, Huang H, Wang L, James JL, Balko JM, Gonzalez-Ericsson PI, Sanders ME, Zhang B, Pietenpol JA, Chen XS. Multi-omics analysis identifies therapeutic vulnerabilities in triple-negative breast cancer subtypes. Nature communications. 2021 Dec 1;12(12). 6276 p.
-
Marshall CB, Beeler JS, Lehmann BD, Gonzalez-Ericsson P, Sanchez V, Sanders ME, Boyd KL, Pietenpol JA. Tissue-specific expression of p73 and p63 isoforms in human tissues. Cell death & disease. 2021 Jul 27;12(12). 745 p.
-
Lu M, Sha Y, Silva TC, Colaprico A, Sun X, Ban Y, Wang L, Lehmann BD, Chen XS. LR Hunting: A Random Forest Based Cell-Cell Interaction Discovery Method for Single-Cell Gene Expression Data. Frontiers in genetics. 12(12). 708835 p.
2020
-
Schafer JM, Lehmann BD, Gonzalez-Ericsson PI, Marshall CB, Beeler JS, Redman LN, Jin H, Sanchez V, Stubbs MC, Scherle P, Johnson KN, Sheng Q, Roland JT, Bauer JA, Shyr Y, Chakravarthy B, Mobley BC, Hiebert SW, Balko JM, Sanders ME, Liu PCC, Pietenpol JA. Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. Science translational medicine. 2020 Dec 11;12(12). NIHMSID: NIHMS1605314.
-
Wang F, Zheng W, Bailey CE, Mayer IA, Pietenpol JA, Shu XO. Racial/Ethnic Disparities in All-Cause Mortality Among Patients Diagnosed with Triple-Negative Breast Cancer. Cancer research. 2020 Dec 3.
-
Lehmann BD, Abramson VG, Sanders ME, Mayer EL, Haddad TC, Nanda R, Van Poznak C, Storniolo AM, Nangia JR, Gonzalez-Ericsson PI, Sanchez V, Johnson KN, Abramson RG, Chen SC, Shyr Y, Arteaga CL, Wolff AC, Pietenpol JA. TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR Metastatic Triple-Negative Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2020 Dec 1;26(26). 2111-2123. NIHMSID: NIHMS1546228.
-
Schafer JM, Pietenpol JA. Tyramide Signal-Amplified Immunofluorescence of MYCN and MYC in Human Tissue Specimens and Cell Line Cultures. Bio-protocol. 2020 Jul 5;10(10). e3677.
2019
-
Lehmann BD, Shaver TM, Johnson DB, Li Z, Gonzalez-Ericsson PI, Sánchez V, Shyr Y, Sanders ME, Pietenpol JA. Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver Mutations. Molecular cancer research : MCR. 2019 Sep;17(17). 1842-1853. NIHMSID: NIHMS1531711.
-
Beeler JS, Marshall CB, Gonzalez-Ericsson PI, Shaver TM, Santos Guasch GL, Lea ST, Johnson KN, Jin H, Venters BJ, Sanders ME, Pietenpol JA. p73 regulates epidermal wound healing and induced keratinocyte programming. PloS one. 14(14). e0218458.
2018
-
Fuertes-Alvarez S, Maeso-Alonso L, Villoch-Fernandez J, Wildung M, Martin-Lopez M, Marshall C, Villena-Cortes AJ, Diez-Prieto I, Pietenpol JA, Tissir F, Lizé M, Marques MM, Marin MC. p73 regulates ependymal planar cell polarity by modulating actin and microtubule cytoskeleton. Cell death & disease. 2018 Dec 5;9(9). 1183 p.
-
Pietenpol JA. p73 Is Required for Ovarian Follicle Development and Regulates a Gene Network Involved in Cell-to-Cell Adhesion. IScience. 2018 Oct 26;8(8). 236-249.
2017
-
Jovanović B, Sheng Q, Seitz RS, Lawrence KD, Morris SW, Thomas LR, Hout DR, Schweitzer BL, Guo Y, Pietenpol JA, Lehmann BD. Comparison of triple-negative breast cancer molecular subtyping using RNA from matched fresh-frozen versus formalin-fixed paraffin-embedded tissue. BMC cancer. 2017 Dec 4;17(17). 241 p.
-
Jovanović B, Mayer IA, Mayer EL, Abramson VG, Bardia A, Sanders ME, Kuba MG, Estrada MV, Beeler JS, Shaver TM, Johnson KC, Sanchez V, Rosenbluth JM, Dillon PM, Forero-Torres A, Chang JC, Meszoely IM, Grau AM, Lehmann BD, Shyr Y, Sheng Q, Chen SC, Arteaga CL, Pietenpol JA. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Aug 1;23(23). 4035-4045. NIHMSID: NIHMS859109.
2016
-
Cowen SD, Russell D, Dakin LA, Chen H, Larsen NA, Godin R, Throner S, Zheng X, Molina A, Wu J, Cheung T, Howard T, Garcia-Arenas R, Keen N, Pendleton CS, Pietenpol JA, Ferguson AD. Design, Synthesis, and Biological Activity of Substrate Competitive SMYD2 Inhibitors. Journal of medicinal chemistry. 2016 Dec 22;59(59). 11079-11097.
-
Shaver TM, Lehmann BD, Beeler JS, Li CI, Li Z, Jin H, Stricker TP, Shyr Y, Pietenpol JA. Diverse, Biologically Relevant, and Targetable Gene Rearrangements in Triple-Negative Breast Cancer and Other Malignancies. Cancer research. 2016 Dec 15;76(76). 4850-60. NIHMSID: NIHMS792009.
-
Ludwik KA, Campbell JP, Li M, Li Y, Sandusky ZM, Pasic L, Sowder ME, Brenin DR, Pietenpol JA, O'Doherty GA, Lannigan DA. Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. Molecular cancer therapeutics. 2016 Dec;15(15). 2598-2608. NIHMSID: NIHMS810239.
-
Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS. Erratum to: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC cancer. 2016 Apr 18;16(16). 275 p.
-
Marshall CB, Mays DJ, Beeler JS, Rosenbluth JM, Boyd KL, Santos Guasch GL, Shaver TM, Tang LJ, Liu Q, Shyr Y, Venters BJ, Magnuson MA, Pietenpol JA. p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. Cell reports. 2016 Mar 15;14(14). 2289-300. NIHMSID: NIHMS760660.
-
Ring BZ, Hout DR, Morris SW, Lawrence K, Schweitzer BL, Bailey DB, Lehmann BD, Pietenpol JA, Seitz RS. Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC cancer. 2016 Feb 23;16(16). 143 p.
-
Lehmann BD, Jovanović B, Chen X, Estrada MV, Johnson KN, Shyr Y, Moses HL, Sanders ME, Pietenpol JA. Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection. PloS one. 11(11). e0157368.
2015
-
Lehmann BD, Pietenpol JA. Clinical implications of molecular heterogeneity in triple negative breast cancer. Breast (Edinburgh, Scotland). 2015 Nov;24 Suppl 2(24 Suppl 2). S36-40. NIHMSID: NIHMS710554.
-
Gallant JN, Sheehan JH, Shaver TM, Bailey M, Lipson D, Chandramohan R, Red Brewer M, York SJ, Kris MG, Pietenpol JA, Ladanyi M, Miller VA, Ali SM, Meiler J, Lovly CM. EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib. Cancer discovery. 2015 Nov;5(5). 1155-63. NIHMSID: NIHMS717408.
-
Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Oncotarget. 2015 Aug 28;6(6). 21353-68.
-
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA. Subtyping of triple-negative breast cancer: implications for therapy. Cancer. 2015 Jan 1;121(121). 8-16. NIHMSID: NIHMS609530.
-
Mohni KN, Thompson PS, Luzwick JW, Glick GG, Pendleton CS, Lehmann BD, Pietenpol JA, Cortez D. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. PloS one. 10(10). e0125482.
-
Lehmann BD, Pietenpol JA, Tan AR. Triple-negative breast cancer: molecular subtypes and new targets for therapy. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting. e31-9.
2014
-
Guo Y, Zhao S, Lehmann BD, Sheng Q, Shaver TM, Stricker TP, Pietenpol JA, Shyr Y. Detection of internal exon deletion with exon Del. BMC bioinformatics. 2014 Oct 16;15(15). 332 p.
-
Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gómez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast cancer research : BCR. 2014 Aug 8;16(16). 406 p.
-
Feigin ME, Akshinthala SD, Araki K, Rosenberg AZ, Muthuswamy LB, Martin B, Lehmann BD, Berman HK, Pietenpol JA, Cardiff RD, Muthuswamy SK. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. Cancer research. 2014 Jun 1;74(74). 3180-94. NIHMSID: NIHMS579974.
-
Mayer IA, Abramson VG, Lehmann BD, Pietenpol JA. New strategies for triple-negative breast cancer--deciphering the heterogeneity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Feb 15;20(20). 782-90. NIHMSID: NIHMS557917.
-
Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, Sánchez V, Kurupi R, Moore PD, Pinto JA, Doimi FD, Gómez H, Horiuchi D, Goga A, Lehmann BD, Bauer JA, Pietenpol JA, Ross JS, Palmer GA, Yelensky R, Cronin M, Miller VA, Stephens PJ, Arteaga CL. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer discovery. 2014 Feb;4(4). 232-45. NIHMSID: NIHMS550472.
-
Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. The Journal of pathology. 2014 Jan;232(232). 142-50. NIHMSID: NIHMS608567.
2011
-
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. The Journal of clinical investigation. 2011 Jul;121(121). 2750-67.